FDA Updates Sartan Recalls; Finds New Impurity FDA Updates Sartan Recalls; Finds New Impurity

Two companies recall losartan products owing to the presence of N-nitroso-N-methyl-4-aminobutyric acid (NMBA), the third type of nitrosamine impurity detected in angiotensin II receptor blockers.News Alerts
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news